Articles published by BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC

December 10, 2025

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS

November 03, 2025

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 24, 2025

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

BlossomHill Therapeutics Announces Upcoming Poster Presentation on Phase 1/2 SOLARA Trial of BH-30643, a First-in-class, Macrocyclic OMNI-EGFR™ Inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 14, 2025

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

August 22, 2025

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President

May 09, 2025

From BlossomHill Therapeutics, Inc.

Via GlobeNewswire

BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting

April 03, 2025

From BlossomHill Therapeutics, Inc.

Via Business Wire

BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer

January 22, 2025

From BlossomHill Therapeutics, Inc.

Via Business Wire

BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President

January 06, 2025

From BlossomHill Therapeutics, Inc.

Via Business Wire

BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering

February 14, 2024

From BlossomHill Therapeutics, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.